novo septerna - Search News

Order byBest matchMost fresh

News

Novo Nordisk Inks A Major Obesity Deal

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Continue reading

· 13h · on MSN

· 10h · on MSN

Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal

· 12h · on MSN

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

7hon MSN

This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results